Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Carol Wysham"'
Publikováno v:
JMIR Formative Research, Vol 7, p e49115 (2023)
BackgroundStrategies for managing type 2 diabetes (T2D) and obesity are evolving with the introduction of targeted therapies, including incretin-based dual agonists and growing knowledge of the importance of multidisciplinary care. Accessible, effect
Externí odkaz:
https://doaj.org/article/56b68e5c66e34d058613f642208be838
Publikováno v:
JMIR Medical Education, Vol 9, p e48586 (2023)
BackgroundDespite guidelines recommending the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in certain patients with type 2 diabetes (T2D), they are not being prescribed for many of these patients. Web-based continuing medical educatio
Externí odkaz:
https://doaj.org/article/070b062e9af4449f9d21226e85240a43
Autor:
Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J. L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. Rodbard, Giuseppe M. C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra-Maria Schumm-Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-16 (2022)
Abstract The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18–19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform fo
Externí odkaz:
https://doaj.org/article/00e116eff4ae44ebb18f8fbed0bc075e
Autor:
R. Daniel Pollom, Carol Wysham, Liza L. Ilag, Dana Sindelar, Yun Chen, Rattan Juneja, Trang T. Ly, Robert C. Hood
Publikováno v:
Endocrine Practice. 27:783-789
Objective We conducted a posthoc analysis of the VIVID study (Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Ra
Autor:
Steven J, Russell, Roy W, Beck, Edward R, Damiano, Firas H, El-Khatib, Katrina J, Ruedy, Courtney A, Balliro, Zoey, Li, Peter, Calhoun, R Paul, Wadwa, Bruce, Buckingham, Keren, Zhou, Mark, Daniels, Philip, Raskin, Perrin C, White, Jane, Lynch, Jeremy, Pettus, Irl B, Hirsch, Robin, Goland, John B, Buse, Davida, Kruger, Nelly, Mauras, Andrew, Muir, Janet B, McGill, Fran, Cogen, Jill, Weissberg-Benchell, Jordan S, Sherwood, Luz E, Castellanos, Mallory A, Hillard, Marwa, Tuffaha, Melissa S, Putman, Mollie Y, Sands, Gregory, Forlenza, Robert, Slover, Laurel H, Messer, Erin, Cobry, Viral N, Shah, Sarit, Polsky, Rayhan, Lal, Laya, Ekhlaspour, Michael S, Hughes, Marina, Basina, Betul, Hatipoglu, Leann, Olansky, Amrit, Bhangoo, Nikta, Forghani, Himala, Kashmiri, Francoise, Sutton, Abha, Choudhary, Jimmy, Penn, Rabab, Jafri, Maria, Rayas, Elia, Escaname, Catherine, Kerr, Ruby, Favela-Prezas, Schafer, Boeder, Subbulaxmi, Trikudanathan, Kristen M, Williams, Natasha, Leibel, M Sue, Kirkman, Kate, Bergamo, Klara R, Klein, Jean M, Dostou, Sriram, Machineni, Laura A, Young, Jamie C, Diner, Arti, Bhan, J Kimberly, Jones, Matthew, Benson, Keisha, Bird, Kimberly, Englert, Joe, Permuy, Kristina, Cossen, Eric, Felner, Maamoun, Salam, Julie M, Silverstein, Samantha, Adamson, Andrea, Cedeno, Seema, Meighan, Carol, Wysham
Publikováno v:
The New England journal of medicine. 387(13)
Currently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting for routine operation. In contrast, the bionic pancreas is initialized
Autor:
Christophe De Block, Clifford Bailey, Carol Wysham, Andrea Hemmingway, Sheryl Elaine Allen, Jennifer Peleshok
Publikováno v:
Diabetes, obesity & metabolism
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes and unde
Autor:
Julio Rosenstock, Carol Wysham, Juan P. Frias, Shizuka Kaneko, Clare J. Lee, Laura Fernández Landó, Huzhang Mao, Xuewei Cui, Vivian T. Thieu, Matthias Blüher
Publikováno v:
Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.
Autor:
April Slee, Kenneth W. Mahaffey, Mary Lee, David R. Matthews, Carol Wysham, Maria Alba, Vlado Perkovic, Bruce Neal, Melanie J. Davies
Publikováno v:
Diabetes, Obesity & Metabolism
This study compared initiation of insulin and other AHAs with canagliflozin versus placebo for participants with type 2 diabetes and a history/high risk of cardiovascular disease in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
Autor:
Jay H. Shubrook, Carol Wysham
Publikováno v:
Postgraduate Medicine. 132:676-686
It is well known that type 2 diabetes mellitus (T2D) is a globally increasing health burden. Despite recent therapeutic advances and the availability of many different classes of antihyperglycemic therapy, a large proportion of people do not achieve
Autor:
Ulrik Pedersen-Bjergaard, Wendy Lane, Athena Philis-Tsimikas, Simon Heller, Lars Bardtrum, Carol Wysham, Signe Harring
Publikováno v:
Diabetes, Obesity & Metabolism
Philis-Tsimikas, A, Lane, W, Pedersen-Bjergaard, U, Wysham, C, Bardtrum, L, Harring, S & Heller, S 2020, ' The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL ', Diabetes, Obesity and Metabolism, vol. 22, no. 5, pp. 779-787 . https://doi.org/10.1111/dom.13954
Philis-Tsimikas, A, Lane, W, Pedersen-Bjergaard, U, Wysham, C, Bardtrum, L, Harring, S & Heller, S 2020, ' The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL ', Diabetes, Obesity and Metabolism, vol. 22, no. 5, pp. 779-787 . https://doi.org/10.1111/dom.13954
Aim\ud \ud Treat‐to‐target, randomized controlled trials have confirmed lower rates of hypoglycaemia at equivalent glycaemic control with insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) in patients with type 1 (T1